Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Recombinant respiratory syncytial virus (RSV) bearing a set of mutations from cold-passaged RSV is attenuated in chimpanzees.

Literature DB >> 9557743

Recombinant respiratory syncytial virus (RSV) bearing a set of mutations from cold-passaged RSV is attenuated in chimpanzees.

S S Whitehead¹, K Juhasz, C Y Firestone, P L Collins, B R Murphy.

Abstract

A set of five missense mutations previously identified by nucleotide sequence analysis of subgroup A cold-passaged (cp) respiratory syncytial virus (RSV) has been introduced into a recombinant wild-type strain of RSV. This recombinant virus, designated rA2cp, appears to replicate less efficiently in the upper and lower respiratory tracts of seronegative chimpanzees than either biologically derived or recombinant wild-type RSV. Infection with rA2cp also resulted in significantly less rhinorrhea and cough than infection with wild-type RSV. These findings confirm the role of the cp mutations in attenuation of RSV and identify their usefulness for inclusion in future live attenuated recombinant RSV vaccine candidates.

Entities: Disease Gene Species

Mesh：

Substances：
DNA, Viral

Year: 1998 PMID： 9557743 PMCID： PMC109683 DOI： 10.1128/JVI.72.5.4467-4471.1998

Source DB: PubMed Journal: J Virol ISSN： 0022-538X Impact factor: 5.103

22 in total

1. IMMUNIZATION AGAINST MEASLES: DEVELOPMENT AND EVALUATION OF A HIGHLY ATTENUATED LIVE MEASLES VACCINE.

Authors: A J SCHWARZ
Journal: Ann Paediatr Date: 1964

2. A mutation present in the amino terminus of Sabin 3 poliovirus VP1 protein is attenuating.

Authors: J M Tatem; C Weeks-Levy; A Georgiu; S J DiMichele; E J Gorgacz; V R Racaniello; F R Cano; S J Mento
Journal: J Virol Date: 1992-05 Impact factor: 5.103

3. Determinants in the 5' noncoding region of poliovirus Sabin 1 RNA that influence the attenuation phenotype.

Authors: N Kawamura; M Kohara; S Abe; T Komatsu; K Tago; M Arita; A Nomoto
Journal: J Virol Date: 1989-03 Impact factor: 5.103

4. Genetic basis of attenuation of the Sabin type 3 oral poliovirus vaccine.

Authors: G D Westrop; K A Wareham; D M Evans; G Dunn; P D Minor; D I Magrath; F Taffs; S Marsden; M A Skinner; G C Schild
Journal: J Virol Date: 1989-03 Impact factor: 5.103

5. An influenza A live attenuated reassortant virus possessing three temperature-sensitive mutations in the PB2 polymerase gene rapidly loses temperature sensitivity following replication in hamsters.

Authors: B R Murphy; E J Park; P Gottlieb; K Subbarao
Journal: Vaccine Date: 1997 Aug-Sep Impact factor: 3.641

6. Four viral genes independently contribute to attenuation of live influenza A/Ann Arbor/6/60 (H2N2) cold-adapted reassortant virus vaccines.

Authors: M H Snyder; R F Betts; D DeBorde; E L Tierney; M L Clements; D Herrington; S D Sears; R Dolin; H F Maassab; B R Murphy
Journal: J Virol Date: 1988-02 Impact factor: 5.103

7. Low-temperature-grown RS virus in adult volunteers.

Authors: W T Friedewald; B R Forsyth; C B Smith; M A Gharpure; R M Chanock
Journal: JAMA Date: 1968-05-20 Impact factor: 56.272

8. Recombinant respiratory syncytial virus from which the entire SH gene has been deleted grows efficiently in cell culture and exhibits site-specific attenuation in the respiratory tract of the mouse.

Authors: A Bukreyev; S S Whitehead; B R Murphy; P L Collins
Journal: J Virol Date: 1997-12 Impact factor: 5.103

9. Genetic factors associated with loss of the temperature-sensitive phenotype of the influenza A/Alaska/77-ts-1A2 recombinant during growth in vivo.

Authors: M D Tolpin; J G Massicot; M G Mullinix; H W Kim; R H Parrott; R M Chanock; B R Murphy
Journal: Virology Date: 1981-07-30 Impact factor: 3.616

10. Clinical and immunological response of infants and children to administration of low-temperature adapted respiratory syncytial virus.

Authors: H W Kim; J O Arrobio; G Pyles; C D Brandt; E Camargo; R M Chanock; R H Parrott
Journal: Pediatrics Date: 1971-11 Impact factor: 7.124

43 in total

1. Analysis of the noncoding regions of measles virus strains in the Edmonston vaccine lineage.

Authors: C L Parks; R A Lerch; P Walpita; H P Wang; M S Sidhu; S A Udem
Journal: J Virol Date: 2001-01 Impact factor: 5.103

2. The major attenuating mutations of the respiratory syncytial virus vaccine candidate cpts530/1009 specify temperature-sensitive defects in transcription and replication and a non-temperature-sensitive alteration in mRNA termination.

Authors: K Juhasz; B R Murphy; P L Collins
Journal: J Virol Date: 1999-06 Impact factor: 5.103

3. Mutations in the 5' trailer region of a respiratory syncytial virus minigenome which limit RNA replication to one step.

Authors: M E Peeples; P L Collins
Journal: J Virol Date: 2000-01 Impact factor: 5.103

Review 4. New generation live vaccines against human respiratory syncytial virus designed by reverse genetics.

Authors: Peter L Collins; Brian R Murphy
Journal: Proc Am Thorac Soc Date: 2005

Review 5. Recent vaccine development for human metapneumovirus.

Authors: J Ren; T Phan; X Bao
Journal: J Gen Virol Date: 2015-02-09 Impact factor: 3.891

6. Enhanced Neutralizing Antibody Response Induced by Respiratory Syncytial Virus Prefusion F Protein Expressed by a Vaccine Candidate.

Authors: Bo Liang; Sonja Surman; Emerito Amaro-Carambot; Barbora Kabatova; Natalie Mackow; Matthias Lingemann; Lijuan Yang; Jason S McLellan; Barney S Graham; Peter D Kwong; Anne Schaap-Nutt; Peter L Collins; Shirin Munir
Journal: J Virol Date: 2015-07-08 Impact factor: 5.103

10. Addition of a missense mutation present in the L gene of respiratory syncytial virus (RSV) cpts530/1030 to RSV vaccine candidate cpts248/404 increases its attenuation and temperature sensitivity.

Authors: S S Whitehead; C Y Firestone; R A Karron; J E Crowe; W R Elkins; P L Collins; B R Murphy
Journal: J Virol Date: 1999-02 Impact factor: 5.103